GT Biopharma, Inc. (GTBP) vs HeartSciences Inc. (HSCS)
Over the past 3 years, GTBP lagged HSCS — -67.44% vs -51.42% annualized total return (price plus dividends).
A side-by-side comparison of GT Biopharma, Inc. and HeartSciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — GTBP vs HSCS
growth of $100 · dividends reinvested · last 4yMetrics side by side
Did GTBP beat HSCS?
Over the past 3 years, GTBP lagged HSCS — -67.44% vs -51.42% annualized total return (price plus dividends).
Total return (annualized)
| Metric | GTBP | HSCS |
|---|---|---|
| Total return (1Y) | -61.33% | 17.75% |
| Total return CAGR (3Y) | -67.44% | -51.42% |
| Total return CAGR (5Y) | -73.13% | N/A |
| Total return CAGR (10Y) | -68.76% | N/A |
HSCS is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has GTBP beaten HSCS?
- Over the past 3 years, GTBP lagged HSCS — -67.44% vs -51.42% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.